| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On December 5, 2007
|
|
|
|
|
|
|
|
|
|
|
| Docket
#
|
| Title
|
|
|
|
|
|
|
| 1978N-0038
|
| Sunscreen Drug Products
|
|
|
|
|
| 2001D-0193
|
| Premarket Notifications for Biological Indicators Intended
|
|
|
|
|
| 2006P-0210
|
| Amend regulations for products composed of engineered nanoparticles generally and sunscreen drug products composed of engineered nanoparticles specifically
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| 2007E-0046
|
| Patent Extension Application for ZILMAX (zilpaterol hydrochloride), U.S. Patent No. 4,900,735
|
|
|
|
|
| 2007N-0262
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designation (Epinephrine)
|
|
|
|
|
| 2007N-0343
|
| Electronic Nonclinical Study Data Submission; Notice of Pilot Project
|
|
|
|
|
| 2007N-0356
|
| BEHIND THE COUNTER AVAILABILITY OF CERTAIN DRUGS; Public Meeting
|
|
|
|
|
| 2007P-0297
|
| Request to reconsider the failure to approve Provenge
|
|
| |
|
| 1978N-0038
|
| Sunscreen Drug Products
|
|
|
|
|
| C 707
|
| International Center for Technology Assessment
|
| Vol #:
|
| 177
|
|
|
|
|
| C 708
|
| Commonwealth of Virginia House of Delegates Richmond
|
| Vol #:
|
| 176
|
|
|
|
|
| C 709
|
| D. Diamond
|
| Vol #:
|
| 176
|
|
|
|
|
| 2001D-0193
|
| Premarket Notifications for Biological Indicators Intended
|
|
|
|
|
| EC 5
|
| None
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006P-0210
|
| Amend regulations for products composed of engineered nanoparticles generally and sunscreen drug products composed of engineered nanoparticles specifically
|
|
|
|
|
| C 4
|
| International Center for Technology Assessment
|
| Vol #:
|
| 6
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| C 492
|
| K. Ellison-Parton
|
| Vol #:
|
| 14
|
|
|
|
|
| C 493
|
| M. Reising
|
| Vol #:
|
| 14
|
|
|
|
|
| C 494
|
| D. Abbott
|
| Vol #:
|
| 14
|
|
|
|
|
| 2007E-0046
|
| Patent Extension Application for ZILMAX (zilpaterol hydrochloride), U.S. Patent No. 4,900,735
|
|
|
|
|
| LET 5
|
| U.S. Patent and Trademark Office to Intervet Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007N-0262
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designation (Epinephrine)
|
|
|
|
|
| C 8
|
| Wyeth Consumer Healthcare
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007N-0343
|
| Electronic Nonclinical Study Data Submission; Notice of Pilot Project
|
|
|
|
|
| LET 4
|
| Novo Nordisk, Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007N-0356
|
| BEHIND THE COUNTER AVAILABILITY OF CERTAIN DRUGS; Public Meeting
|
|
|
|
|
| TS 18
|
| American Medical Association
|
| Vol #:
|
| 3
|
|
|
|
|
| TS 19
|
| Food Marketing Institute
|
| Vol #:
|
| 3
|
|
|
|
|
| TS 20
|
| Health Research Group at Public Citizen
|
| Vol #:
|
| 3
|
|
